
Prediction: This Will Be the First Mega Technology Company to Split Its Stock in 2025 (and It Isn't Tesla)
Stock splits garner a lot of attention from individual investors. While they do not have an impact on the stock's underlying business, they can draw more attention to the company. Many of the "Magnificent Seven" stocks have split their shares during the past few years, including the likes of Tesla, Apple, and Amazon, as these companies become larger parts of the world economy.
One technology stock that has been suspiciously absent from the stock split game is Netflix (NASDAQ: NFLX). The video entertainment giant last split its stock in 2015. With the shares approaching $1,200, it is just about time for Netflix to split its stock once again in 2025. But does that make it a buy for your portfolio? Let's run the numbers and find out.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Netflix's steady growth
Consistent growth has been the name of the game for Netflix despite a wild macroeconomic backdrop during the past five years. Revenue has climbed to more than $40 billion during the past 12 months compared to less than $10 billion 10 years ago. Operating income has ballooned from roughly breakeven to more than $11 billion as the company further extends its lead in streaming video around the world.
At the end of 2024, Netflix had more than 300 million global paid streaming memberships. This may seem like a lot, but there is plenty of room for streaming video to disrupt linear video in the years to come. For example, Netflix shared that about half of TV viewing in the U.K. still comes from legacy providers. Over the long term, many of these viewers will transition to video streaming, providing a long-term tailwind for Netflix even at its immense size.
Netflix's stock is up more than 1,000% during the past 10 years. A big reason for these gains is the company's operating leverage and pricing power. Operating margin has widened to 28% during the past 12 months, making Netflix one of the most profitable businesses in the world.
Expanding into advertising and sports
There is still a lot of room for Netflix to expand, especially outside of the U.S. In Asia, the company had fewer than 60 million subscribers at the end of 2024, providing plenty of room to gain market share on the continent with billions of potential subscribers.
In its more mature markets, Netflix is aiming to increase revenue by adding new content and monetization techniques. It has expanded into live events, such as the Tom Brady Roast, and has dipped its toe into sports content. Christmas Day games for the National Football League were a hit, and the company now has a long-term contract with World Wrestling Entertainment (WWE), which has millions of fans. Sports viewing is a huge part of the video streaming landscape, and Netflix now believes it can capture a piece of this pie.
To monetize sports -- as well as its full library of content -- Netflix has started to offer an advertising tier. At $8 a month in the U.S., people can now access Netflix with advertisements, which only launched a few years back. Reportedly, 40% of new subscribers in the U.S. have the advertising tier, and while we do not know exactly how much in advertising sales the company is making today, there is a huge runway to expand these services, given how much time people spend watching Netflix.
NFLX PE Ratio data by YCharts
The truth about a Netflix stock split
With steady revenue growth and a lofty stock price, I think Netflix will split its stock again in 2025. The last time it did so was in 2015.
However, investors need to understand that this has no bearing on whether Netflix stock is a buy.
Why? Because a stock split does not change anything about Netflix's underlying business or market capitalization. All it would do is separate the Netflix pie into smaller pieces. If you had one share before and there's a 10-for-1 split, those 10 new shares are still going to be worth the same dollar amount. The actual business is not impacted at all.
Today, Netflix has a market cap of about $500 billion, and a price-to-earnings ratio (P/E) of 56. This is not cheap, even for a steady growth stock like Netflix. Regardless of whether Netflix is going to split its stock in 2025, this is an expensive stock that is probably not a buy today. Conversely, it is because Netflix stock has soared and gotten so expensive that the stock is ready to split, meaning a stock-split stock may be an indicator of a bad future investment.
Stay away from Netflix stock for the time being.
Should you invest $1,000 in Netflix right now?
Before you buy stock in Netflix, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Netflix wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!*
Now, it's worth noting Stock Advisor 's total average return is957% — a market-crushing outperformance compared to167%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Brett Schafer has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Apple, Netflix, and Tesla. The Motley Fool has a disclosure policy.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
38 minutes ago
- National Post
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only
Article content GENT, Belgium & MALVERN, Pa. & TOKYO — H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in human cerebrospinal fluid (CSF) and blood within just 35 minutes. Article content sTREM2 is a promising biomarker of microglial activation, offering researchers insights into neuroinflammation linked to Alzheimer's and other neurodegenerative diseases. sTREM2 can be valuable for capturing the dynamics of inflammatory responses or for monitoring inflammatory modulators. This test complements Fujirebio's growing portfolio of neuro biomarkers, including GFAP, NfL, and pTau, and reinforces the company's leading position in advancing neuro biomarker research tools and diagnostics. Article content Article content 'By adding sTREM2 to our neuro portfolio, we're enabling a more comprehensive view of neurological disease mechanisms,' Article content said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. 'sTREM2 complements established biomarkers like GFAP, NfL, and pTau by adding essential insight into neuroinflammation – offering a more complete picture of the disease on a single platform.' Article content The new test allows researchers and clinical research professionals to further study and understand the potential clinical utility of this promising microglial biomarker. The availability of the assay on the fully automated random access LUMIPULSE G analyzers gives researchers access to convenient, accurate, and robust measurement of sTREM2. Already widely available for routine use in neurological disease testing worldwide, these analyzers meet all necessary quality, throughput, and regulatory requirements. Article content About Fujirebio Article content Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Article content Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. Article content Article content Article content Email: Article content pr@ Article content For investors and analysts: Article content Article content IR/SR Dept. Article content Article content Article content

CTV News
2 hours ago
- CTV News
CTV National News: Steel and aluminum tariffs doubled as Trump's trade war escalates
CTV National News: Steel and aluminum tariffs doubled as Trump's trade war escalates Prime Minister Carney is calling U.S. President Trump's doubling of steel and aluminum tariffs 'unlawful and unjustified'. Rachel Aiello has the latest.


CBC
2 hours ago
- CBC
Bank of Canada officials speak after interest rate announcement
Bank of Canada governor Tiff Macklem and senior deputy governor Carolyn Rogers give a statement and answer questions about the central bank's interest rate announcement.